Cochrane · systematic review · CD012406

Macrolide antibiotics for bronchiectasis

Kelly, C, Chalmers, JD, Crossingham, I, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library

AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
15
No studies
7
Included studies
NR
No studies 7 · 31.8%Ungraded 0 · 0%Very low 1 · 4.5%Low 9 · 40.9%Moderate 5 · 22.7%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Macrolides compared with placebo for adults with bronchiectasis

Population: adults with bronchiectasis
6 questions
OutcomeEffectEvidenceStatus / GRADE
≥ 1 exacerbation
Macrolides vs placebo
OR 0.34 [0.22, 0.54]3 studies · 341 participantsModerate
Hospitalisation: all cause
Macrolides vs placebo
OR 0.56 [0.19, 1.62]2 studies · 151 participantsLow
Downgraded: risk of bias, imprecision
Serious adverse events
Macrolides vs placebo
OR 0.49 [0.2, 1.23]3 studies · 326 participantsLow
Downgraded: risk of bias, imprecision
All‐cause mortality
Macrolides vs placebo
no estimate extracted7 studies · 540 participantsLow
Downgraded: risk of bias, imprecision
Quality of life: endpoint
Macrolides vs placebo
no estimate extracted1 study · 68 participantsModerate
Downgraded: risk of bias, imprecision
Quality of life: change
Macrolides vs placebo
no estimate extracted4 studies · 305 participantsLow
Downgraded: risk of bias, imprecision

Macrolides compared with no intervention for adults with bronchiectasis

Population: adults with bronchiectasis
6 questions
OutcomeEffectEvidenceStatus / GRADE
≥ 1 exacerbation
Macrolides vs no intervention
OR 0.31 [0.08, 1.15]1 study · 43 participantsModerate
Hospitalisations ‐ not reported
Macrolides vs no intervention
no estimate extractedNRNo studies
Serious adverse events ‐ not reported
Macrolides vs no intervention
no estimate extractedNRNo studies
Mortality
Macrolides vs no intervention
no estimate extracted2 studies · 88 participantsVery low
QoL SGRQ: endpoint total score Scale from 0 to 100
Macrolides vs no intervention
no estimate extracted2 studies · 89 participantsModerate
QoL SGRQ: change in total score Scale from 0 to 100
Macrolides vs no intervention
no estimate extracted1 study · 30 participantsModerate

Macrolides compared with placebo for children with bronchiectasis

Population: children with bronchiectasis
5 questions
OutcomeEffectEvidenceStatus / GRADE
Exacerbation frequency
Macrolides vs placebo
IRR 0.51 study · 89 participantsLow
Downgraded: imprecision
Hospitalisation: all‐cause
Macrolides vs placebo
OR 0.28 [0.07, 1.11]1 study · 89 participantsLow
Downgraded: imprecision
Serious adverse events
Macrolides vs placebo
OR 0.43 [0.17, 1.05]1 study · 89 participantsLow
Downgraded: imprecision
Mortality
Macrolides vs placebo
no estimate extracted1 study · 42 participantsLow
Downgraded: risk of bias, imprecision
Quality of life not reported
Macrolides vs placebo
no estimate extractedNRNo studies

Macrolides compared with no intervention for children with bronchiectasis

Population: children with bronchiectasis
5 questions
OutcomeEffectEvidenceStatus / GRADE
Exacerbations ‐ not reported
Macrolides vs no intervention
no estimate extractedNRNo studies
Hospitalisation ‐ not reported
Macrolides vs no intervention
no estimate extractedNRNo studies
Serious adverse events ‐ not reported
Macrolides vs no intervention
no estimate extractedNRNo studies
Mortality
Macrolides vs no intervention
no estimate extracted1 study · 34 participantsLow
Quality of life ‐ not reported
Macrolides vs no intervention
no estimate extractedNRNo studies